Jennison Associates’s Iovance Biotherapeutics IOVA Stock Holding History

Jennison Associates’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-66,568	Closed	-$493K	–	606
2024 Q4	$493K	Buy	+66,568	New	+$617K	﹤0.01%	558
2024 Q3	–	Sell	-58,084	Closed	-$466K	–	592
2024 Q2	$466K	Buy	58,084 +8,055	+16%	+$86.3K	﹤0.01%	552
2024 Q1	$741K	Sell	50,029 -41,126	-45%	-$479K	﹤0.01%	526
2023 Q4	$741K	Buy	+91,155	New	+$477K	﹤0.01%	524
2021 Q1	–	Sell	-336,986	Closed	-$15.6M	–	702
2020 Q4	$15.6M	Sell	336,986 -9,496	-3%	-$377K	0.01%	362
2020 Q3	$11.4M	Buy	346,482 +1,243	+0.4%	+$38.1K	0.01%	366
2020 Q2	$9.48M	Buy	+345,239	New	+$11.3M	0.01%	378

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Jennison Associates's IOVA Position: Q1 2025 in Review

Jennison Associates sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 66,568 shares — an estimated $493K sold.

Jennison Associates first reported a position in IOVA in Q2 2020 and held it in 7 quarters. The position peaked at $15.6M in Q4 2020. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

Jennison Associates reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
Jennison Associates sold 66,568 Iovance Biotherapeutics shares in Q1 2025, an estimated $493K.
Jennison Associates first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 7 quarters.
Jennison Associates's Iovance Biotherapeutics position peaked at $15.6M in Q4 2020.
302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Jennison Associates's 13F filing for Q1 2025, filed 5 May 2025.